secwatch.observer — SEC 8-K summary
======================================

Issuer:     Denali Therapeutics Inc. (DNLI)
CIK:        0001714899
Form:       8-K
Filed at:   2022-07-05T23:59:59+00:00
Accession:  0001714899-22-000105
Event type: regulatory
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali receives CTA clearance for DNL919 Phase 1 study; FDA clinical hold remains unresolved
--------------------------------------------------------------------------------

- Denali receives CTA clearance to initiate Phase 1 study of DNL919 (ATV:TREM2) in healthy volunteers in the Netherlands.
- Phase 1 single ascending dose study expected to start in Q3 2022.
- FDA clinical hold on DNL919 IND remains; Denali has not yet submitted response.
- Continues engagement with FDA and European regulators to define path forward, including Phase 1b in Alzheimer's.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1714899/000171489922000105/0001714899-22-000105-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1714899/000171489922000105/dnli-20220704.htm
  HTML page:      https://secwatch.observer/filing/0001714899-22-000105

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer